BioCryst Pharmaceuticals Inc (BCRX) Stock: What Does the Chart Say Thursday?

BioCryst Pharmaceuticals Inc (BCRX) stock has gained 8.75% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

BioCryst Pharmaceuticals Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on BCRX!

See Full BCRX Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With BCRX Stock Today?

BioCryst Pharmaceuticals Inc (BCRX) stock is higher by 7.55% while the S&P 500 is lower by -0.24% as of 1:26 PM on Thursday, Nov 30. BCRX has risen $0.41 from the previous closing price of $5.43 on volume of 1,467,591 shares. Over the past year the S&P 500 has gained 14.71% while BCRX is lower by -53.80%. BCRX lost -$1.25 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for BioCryst Pharmaceuticals Inc click here.

More About BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology. Click Here to get the full Stock Report for BioCryst Pharmaceuticals Inc stock.